Cochrane review questions value of pioglitazone

摘要

The value of pioglitazone(Actos)in the treatment of type 2 diabetes mellitus is questioned in a new Cochrane review.The reviewers,led by Bernd Richter,department of endocrinology,diabetes and rheumatology at Heinrich-Heine University,Dusseldorf,Germany,examined data from 22 randomised controlled trials involving 6,200 patients.All trials included in the review had to last at least 24 weeks.